Clinical Trials Logo
  1. Home
  2. AMD
  3. NCT04177069

Evaluate the Improving Effects of Visucomplex Plus on Quality of Life in Patients With AMD

AMD Clinical Trial

Official title:
Real World Study to Evaluate the Improving Effects of Visucomplex Plus on Quality of Life in Patients With Dry and Wet Age-related Macular Degeneration (AMD)

Clinical Trial Summary

This is an observational study in which patients affected by dry or wet AMD will be enrolled, after signing the Informed Consent, according to eligibility criteria.

Patients, after signing the Informed Consent, will enter into a screening phase during which the concomitant medication, clinical history, physical examination (including smoking habits) will be checked and the inclusion/exclusion criteria will be assessed.

Then, at the time of Baseline visit (V0) the eligible patients will be given Visucomplex Plus as monotherapy, 1 capsule daily after food, or for dry or wet AMD patients under treatment with a stable dose of an anti-VEGF drug, Visucomplex Plus, 1 capsule daily after food, upon physical decision.

Screening phase and the baseline visit (V0) could coincide.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04177069
Study type Observational
Source VISUfarma SpA
Contact Anna Rita Bigioni
Phone +39 06 3630 6842
Email a.bigioni@visufarma.com
Status Recruiting
Phase
Start date December 11, 2019
Completion date December 30, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT01432847 - Cell Collection to Study Eye Diseases
Recruiting NCT03893474 - Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners N/A
Completed NCT00971464 - Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation Phase 2
Terminated NCT00332657 - Anecortave Acetate Risk Reduction Trial (AART) Phase 3
Recruiting NCT04796545 - Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration N/A
Active, not recruiting NCT01766596 - Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort) N/A
Completed NCT03322930 - Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)
Completed NCT01778491 - AMD Phenotype and Genotype Study
Completed NCT01016873 - INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD Phase 2
Active, not recruiting NCT03845582 - Phase 3 Study of ALK-001 in Geographic Atrophy Phase 3
Completed NCT03372746 - Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration
Completed NCT03367767 - Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On
Terminated NCT00333216 - Anecortave Acetate Risk-Reduction Trial (AART) Phase 3
Completed NCT01570790 - Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT00346866 - Anecortave Acetate Versus Placebo in AMD Patients Following PDT Phase 2
Withdrawn NCT00726466 - Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration Phase 1
Completed NCT00306488 - OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration Phase 2
Terminated NCT02348359 - X-82 to Treat Age-related Macular Degeneration Phase 2
Completed NCT01632527 - Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD) Phase 1/Phase 2
Withdrawn NCT01339949 - Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV) N/A